Global Rx-360 Consortium Aims To Curb Supply Chain Threats
This article was originally published in The Tan Sheet
Executive Summary
Drug manufacturers formed the Rx-360 consortium as a vanguard in protecting the global supply chain of ingredients for Rx and nonprescription drug products from threats like the heparin adulteration potentially linked to 146 U.S. deaths in 2008
You may also be interested in...
FDA Seeks Public Input On Secrets Of Profit-Motivated Adulteration
FDA plans to hold a public workshop this spring to begin the task of combating profit-motivated adulteration of regulated products
FDA Strengthens Inspections Of Chinese Drug Firms In Heparin Aftermath
BEIJING - As FDA leaders select inspectors to deploy across three offices being set up in China, the agency is also preparing to ramp up the number of inspections and the level of scrutiny of Chinese drug manufacturers that export to the U.S
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.